Published Online
on June 8, 2006

A more recent version of this article appeared on July 1, 2006

This Article Full Text (PDF) All Versions of this Article: 37/7/1798    most recent 01.STR.0000226897.43749.27v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanne, D. Search for Related Content PubMed PubMed Citation Articles by Tanne, D. Related Collections Acute Cerebral Infarction Emergency treatment of Stroke Thrombolysis Coagulation and fibronolysis

Submitted on February 2, 2006
Revised on March 2, 2006
Accepted on March 15, 2006

Hemostatic Activation and Outcome After Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke

David Tanne MD^*; Richard F. Macko MD; Yan Lin PhD; Barbara C. Tilley PhD; Steven R. Levine MD; for the NINDS rtPA Stroke Study Group

From the Stroke Center, Department of Neurology, Chaim Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Israel (D.T.); Department of Neurology and Medicine, Baltimore Veterans Affairs Medical Center, University of Maryland School of Medicine, Baltimore (R.F.M.); Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston (Y.L., B.C.T.); and Stroke Program, Department of Neurology, Mount Sinai School of Medicine, New York, NY (S.R.L.).

^* To whom correspondence should be addressed. E-mail: tanne{at}post.tau.ac.il.

Background and Purpose--Early thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) improves clinical outcome in acute ischemic stroke (AIS), but impaired endogenous fibrinolysis, thrombin generation, and vascular injury may hamper the efficacy of thrombolysis. We investigated in an exploratory, post hoc analysis the relationship between hemostatic markers and clinical outcomes among patients included in the National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Study.

Methods--Tissue plasminogen activator (tPA) antigen, thrombin-antithrombin complex (TAT), soluble thrombomodulin, and fibrinogen levels were measured in patients with AIS included in the NINDS rtPA Stroke Study from plasma samples collected at baseline, at 2 hours after treatment, and after 24 hours.

Results--TAT and tPA antigen levels peaked at 2 hours selectively in the rtPA treatment group, whereas fibrinogen levels dropped at 2 hours and remained low after 24 hours (P<0.0001 for interaction effects between time and treatment). At 24 hours, higher levels of tPA antigen were associated with a lower chance of favorable outcome (odds ratio [OR]=0.34; 95% CI, 0.14 to 0.82) selectively in the rtPA group, and higher levels of TAT (OR=1.72; 95% CI, 1.26 to 2.34) in the entire cohort and of thrombomodulin selectively in the rtPA group (OR=4.45; 95% CI, 1.26 to 15.67) were associated with higher 3-month mortality.

Conclusions--Hemostatic activation after AIS appears to be independently associated with clinical outcome in patients treated with rtPA. However, because we have tested for multiple associations, some may have been identified by chance alone and require further confirmatory studies. On the basis of this exploratory analysis, there is a rationale to investigate the safety and efficacy of protocols in which rtPA is complemented by agents that are antithrombotic and enhance fibrinolysis.

Key words: hemostasis • stroke, acute • thrombolysis

This article has been cited by other articles:

				D. E. Levy, G. J. del Zoppo, B. M. Demaerschalk, A. M. Demchuk, H.-C. Diener, G. Howard, M. Kaste, A. M. Pancioli, C. Spatareanu, and W. W. Wasiewski Ancrod in Acute Ischemic Stroke: Results of 500 Subjects Beginning Treatment Within 6 Hours of Stroke Onset in the Ancrod Stroke Program Stroke, December 1, 2009; 40(12): 3796 - 3803. [Abstract] [Full Text] [PDF]

				G. J. del Zoppo, D. E. Levy, W. W. Wasiewski, A. M. Pancioli, A. M. Demchuk, J. Trammel, B. M. Demaerschalk, M. Kaste, G. W. Albers, and E. B. Ringelstein Hyperfibrinogenemia and Functional Outcome From Acute Ischemic Stroke Stroke, May 1, 2009; 40(5): 1687 - 1691. [Abstract] [Full Text] [PDF]

				J. Marti-Fabregas, M. Borrell, D. Cocho, S. Martinez-Ramirez, M. Martinez-Corral, J. Fontcuberta, and J.-L. Marti-Vilalta Change in Hemostatic Markers After Recombinant Tissue-Type Plasminogen Activator Is Not Associated With the Chance of Recanalization Stroke, January 1, 2008; 39(1): 234 - 236. [Abstract] [Full Text] [PDF]